Raytheon awarded $71 million in Navy contracts for missile systems
iRhythm Technologies Inc . (NASDAQ:IRTC) stock soared to a 52-week high, reaching $147.00, marking a significant milestone for the digital healthcare solutions provider. With a market capitalization of $4.6 billion, the company has demonstrated strong momentum, though InvestingPro analysis indicates the stock is currently trading in overbought territory. This peak reflects a robust year for iRhythm, with the stock witnessing an impressive 51.82% increase over the past year. The company has achieved notable revenue growth of 20.5% over the last twelve months, though it remains unprofitable during this period. Investors have shown growing confidence in the company’s innovative approach to cardiac monitoring and diagnostics, which has been reflected in the stock’s strong performance. The 52-week high serves as a testament to iRhythm’s expanding market presence and its potential for continued growth in the digital health sector. For deeper technical analysis and 11 additional key insights about IRTC, check out the comprehensive research available on InvestingPro.
In other recent news, iRhythm Technologies reported a strong first quarter for 2025, with revenue reaching $158.7 million, marking a 20.3% increase from the previous year. This revenue surpassed both Canaccord’s estimate of $152.6 million and the consensus estimate of $153.4 million. The company also reported an adjusted net loss per share of $0.95, slightly better than the forecasted $0.96. Following these results, iRhythm raised its full-year 2025 revenue guidance to between $690 million and $700 million. Analyst firms have reacted to these developments with varied adjustments to their price targets for iRhythm. Wells Fargo (NYSE:WFC) upgraded the stock from Equal Weight to Overweight, setting a new price target of $130, citing confidence in the company’s business trends and guidance. Canaccord Genuity maintained a Buy rating but lowered its price target to $139 due to a compression in the comparable group, while BTIG raised its target to $140, reflecting strong sales performance. Additionally, iRhythm is on track with its regulatory goals and has launched its commercial operations in Japan, where reimbursement rates are currently aligned with traditional Holter monitors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.